LGVN Longeveron Inc.
Longeveron Inc. (LGVN) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $1.70 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -27.2% since its last earnings release on November 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.